NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, Price Target & More

$157.95 -0.77 (-0.49 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$157.95

Today's Range$156.69 - $159.01

52-Week Range$128.58 - $163.75

Volume259,664 shs

Average Volume413,298 shs

Market Capitalization$9.45 billion

P/E Ratio16.52

Dividend YieldN/A

Beta0.97

About Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:JAZZ

CUSIPG5087110

Webwww.jazzpharma.com

Phone353-1634-7800

Debt

Debt-to-Equity Ratio0.57%

Current Ratio3.29%

Quick Ratio3.15%

Price-To-Earnings

Trailing P/E Ratio16.52

Forward P/E Ratio13.76

P/E Growth0.83

Sales & Book Value

Annual Sales$1.62 billion

Price / Sales5.84

Cash Flow$13.0214 per share

Price / Cash12.13

Book Value$45.26 per share

Price / Book3.49

Profitability

EPS (Most Recent Fiscal Year)$9.56

Net Income$487.84 million

Net Margins30.14%

Return on Equity22.63%

Return on Assets10.74%

Miscellaneous

Employees1,210

Outstanding Shares59,800,000

How to Become a New Pot Stock Millionaire

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the consensus estimate of $2.73 by $0.15. The specialty pharmaceutical company earned $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. View Jazz Pharmaceuticals' Earnings History.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Jazz Pharmaceuticals.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of $12.65-13.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.00. The company issued revenue guidance of $1.86-1.93 billion, compared to the consensus revenue estimate of $1.85 billion.

What price target have analysts set for JAZZ?

21 brokerages have issued 1 year target prices for Jazz Pharmaceuticals' shares. Their predictions range from $150.00 to $206.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $181.8452 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:

1. According to Zacks Investment Research, "Jazz lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. Xyrem is facing patent challenges in the United States. Jazz has also been facing difficulties in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setback too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market. Shares of the company outperformed the industry in the last one year." (1/12/2018)
2. Cantor Fitzgerald analysts commented, "Cantor Fitzgerald will host a physician conference call on Tuesday to provide perspective on pitolisant as it relates to JAZZ’s sleep franchise. The call is at 1:00pm EST and the dial in number can be obtained from your Cantor sales rep. Note that the call will be 30 minutes in duration. Questions for the consultant can be emailed to [email protected]" (12/3/2017)

Who are some of Jazz Pharmaceuticals' key competitors?

Some companies that are related to Jazz Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Nektar Therapeutics (NKTR), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), BeiGene (BGNE), Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO) and Gal�pagos (GLPG).

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the folowing people:

Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
Dr. Karen L. Smith, Chief Medical Officer and Exec. VP of R&D (Age 50)
Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

News coverage about JAZZ stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a news impact score of 0.11 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 46.18 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $157.95.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $9.45 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]

MarketBeat Community Rating for Jazz Pharmaceuticals (JAZZ)

Community Ranking:		3.7 out of 5 ( )
Outperform Votes:		755 (Vote Outperform)
Underperform Votes:		257 (Vote Underperform)
Total Votes:		1,012

MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

21 Wall Street analysts have issued ratings and price targets for Jazz Pharmaceuticals in the last 12 months. Their average twelve-month price target is $181.8452, suggesting that the stock has a possible upside of 15.13%. The high price target for JAZZ is $206.00 and the low price target for JAZZ is $150.00. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.81	2.80	2.76	2.77
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$181.8452	$182.1875	$180.3810	$181.9091
Price Target Upside:	15.13% upside	20.91% upside	20.10% upside	29.79% upside

Jazz Pharmaceuticals (NASDAQ:JAZZ) Consensus Price Target History

Price Target History for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/6/2018	Seaport Global Securities	Set Price Target	Buy	$175.00	Low
3/23/2018	HC Wainwright	Reiterated Rating	Neutral	$150.00 -> $160.00	Medium
3/19/2018	Morgan Stanley	Upgrade	Equal Weight -> Overweight	$128.58 -> $163.75	High
3/1/2018	Piper Jaffray	Reiterated Rating	Buy	$201.00	Low
2/28/2018	BMO Capital Markets	Boost Price Target	Outperform -> Outperform	$196.00 -> $199.00	High
2/20/2018	Bank of America	Boost Price Target	Buy -> Buy	$164.00 -> $170.00	Low
1/16/2018	B. Riley	Reiterated Rating	Buy	$206.00	Low
1/16/2018	Deutsche Bank	Set Price Target	Buy	$170.00	Medium
1/2/2018	Leerink Swann	Initiated Coverage	Outperform -> Outperform	$180.00	Low
12/25/2017	Wells Fargo	Reiterated Rating	Buy		Low
12/10/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$200.00	Low
12/5/2017	Mizuho	Boost Price Target	Neutral -> Neutral	$144.00 -> $150.00	Low
11/8/2017	UBS	Lower Price Target	Buy	$172.00 -> $168.00	N/A
11/8/2017	Royal Bank of Canada	Lower Price Target	Outperform	$210.00 -> $195.00	N/A
10/26/2017	Stifel Nicolaus	Reiterated Rating	Buy	$190.00	N/A
10/23/2017	Cowen	Set Price Target	Buy	$190.00	N/A
10/19/2017	FBR & Co	Initiated Coverage	Buy -> Buy	$206.00	N/A
9/28/2017	Goldman Sachs	Initiated Coverage	Neutral -> Neutral	$165.00	Low
9/18/2017	JPMorgan Chase	Reiterated Rating	Buy	$190.00	Low
8/9/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$180.00 -> $192.00	Low
5/22/2017	Sanford C. Bernstein	Set Price Target	Market Perform	$160.00 -> $176.00	Low
2/22/2017	Evercore ISI	Initiated Coverage	Buy	$160.00	N/A
2/16/2017	Guggenheim	Reiterated Rating	Buy		N/A
1/19/2017	SunTrust Banks	Reiterated Rating	Buy	$210.00	N/A
1/18/2017	Barclays	Reiterated Rating	Overweight	$200.00	N/A

(Data available from 4/22/2016 forward)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earnings History and Estimates Chart

Earnings by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earnings Estimates

Current Year EPS Consensus Estimate: $11.48 EPS
Next Year EPS Consensus Estimate: $13.94 EPS

Jazz Pharmaceuticals (NASDAQ JAZZ) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		$2.76					N/A
2/27/2018	Q4 2017	$2.73	$2.58	$440.91 million	$436.40 million	View	N/A
11/7/2017	Q3 2017	$2.53	$2.93	$420.67 million	$411.86 million	View	N/A
8/8/2017	6/30/2017	$1.85	$1.72	$410.83 million	$394.39 million	View	Listen
5/9/2017	3/31/2017	$1.42	$1.41	$376.58 million	$376.10 million	View	Listen
2/28/2017	Q416	$2.65	$1.91	$398.91 million	$396.62 million	View	Listen
11/8/2016	Q316	$2.61	$2.16	$389.34 million	$374.00 million	View	Listen
8/9/2016	Q216	$2.80	$2.63	$376.40 million	$381.00 million	View	N/A
5/10/2016	Q1	$2.31	$2.26	$338.86 million	$336.00 million	View	Listen
2/23/2016	Q415	$2.60	$2.60	$349.98 million	$340.90 million	View	Listen
11/9/2015	Q315	$2.56	$2.52	$348.15 million	$340.90 million	View	Listen
8/5/2015	Q215	$2.41	$2.41	$335.58 million	$333.70 million	View	Listen
5/7/2015	Q115	$2.15	$1.99	$309.50 million	$309.30 million	View	Listen
2/24/2015	Q414	$2.30	$2.44	$319.74 million	$328.10 million	View	Listen
11/4/2014	Q314	$1.98	$2.33	$302.90 million	$306.58 million	View	Listen
8/5/2014	Q214	$1.92	$2.05	$273.39 million	$291.23 million	View	Listen
5/8/2014	Q114	$1.79	$1.61	$254.86 million	$247.00 million	View	Listen
2/25/2014	Q413	$1.78	$1.72	$238.12 million	$235.80 million	View	Listen
11/5/2013	Q313	$1.67	$1.78	$227.38 million	$232.20 million	View	Listen
8/6/2013	Q2 2013	$1.52	$1.43	$208.71 million	$208.30 million	View	Listen
5/7/2013	Q1 2013	$1.35	$1.37	$189.92 million	$196.20 million	View	Listen
2/26/2013	Q4 2012	$1.41	$1.53	$183.80 million	$183.70 million	View	Listen
11/8/2012	Q312	$1.31	$1.29	$178.57 million	$175.50 million	View	N/A
8/7/2012		$1.05	$1.09			View	N/A
5/8/2012		$0.90	$0.91			View	N/A
2/27/2012	Q4 2011	$1.01	$0.96			View	N/A
11/1/2011		$0.89	$0.94			View	N/A
7/28/2011		$0.67	$0.82			View	N/A
5/3/2011		$0.57	$0.59			View	N/A
3/7/2011		$0.60	$0.63			View	N/A
11/4/2010	Q3 2010	$0.29	$0.32			View	N/A
8/10/2010	Q2 2010	$0.14	$0.17			View	N/A
5/5/2010	Q1 2010	$0.14	$0.12			View	N/A
3/3/2010	Q4 2009	$0.05	$0.17			View	N/A
11/5/2009	Q3 2009	($0.14)	($0.05)			View	N/A
8/11/2009	Q2 2009	($0.33)	$0.08			View	N/A
5/7/2009	Q1 2009		($0.45)			View	N/A
3/26/2009	Q4 2008	($1.08)	($0.97)			View	N/A
11/13/2008	Q3 2008	($1.25)	($1.07)			View	N/A
8/7/2008	Q2 2008	($1.74)	($2.18)			View	N/A
5/13/2008	Q1 2008	($1.65)	($1.97)			View	N/A
2/13/2008	Q4 2007	($1.87)	($1.64)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 91.21%

Insider Trading History for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Matthew P Young	CFO	Sell	700	$156.01	$109,207.00	38,465
4/13/2018	Michael Patrick Miller	EVP	Sell	200	$157.49	$31,498.00	27,481
4/10/2018	Karen J Wilson	SVP	Sell	3,899	$155.00	$604,345.00	19,517
4/2/2018	Bruce C Cozadd	CEO	Sell	1,000	$150.01	$150,010.00	293,542
3/15/2018	Matthew P Young	CFO	Sell	700	$151.22	$105,854.00	39,165
3/14/2018	Michael Patrick Miller	EVP	Sell	200	$151.12	$30,224.00	27,681
3/9/2018	Bruce C Cozadd	CEO	Sell	1,000	$150.00	$150,000.00	294,542
3/6/2018	Matthew P Young	CFO	Sell	1,152	$142.36	$163,998.72
3/6/2018	Paul Treacy	SVP	Sell	594	$141.47	$84,033.18
3/2/2018	Paul Treacy	SVP	Sell	877	$139.62	$122,446.74
2/28/2018	Bruce C Cozadd	CEO	Sell	1,000	$150.00	$150,000.00	267,468
2/28/2018	Matthew P Young	CFO	Sell	3,135	$146.85	$460,374.75
2/14/2018	Michael Patrick Miller	EVP	Sell	200	$139.99	$27,998.00	21,469
1/16/2018	Matthew P. Young	CFO	Sell	700	$152.16	$106,512.00
1/12/2018	Bruce C. Cozadd	CEO	Sell	3,000	$150.00	$450,000.00
1/12/2018	Michael Patrick Miller	EVP	Sell	200	$148.65	$29,730.00	21,669
12/11/2017	Michael Patrick Miller	EVP	Sell	200	$139.15	$27,830.00
12/11/2017	Patrick G. Enright	Director	Sell	9,000	$139.73	$1,257,570.00
11/17/2017	Iain Mcgill	SVP	Sell	8,000	$133.42	$1,067,360.00	28,383
11/17/2017	Patrick G Enright	Director	Sell	352	$133.19	$46,882.88	1,365
10/2/2017	Bruce C Cozadd	CEO	Sell	1,000	$150.00	$150,000.00
9/12/2017	Bruce C. Cozadd	CEO	Sell	1,000	$153.52	$153,520.00
8/25/2017	Patrick G Enright	Director	Sell	351	$148.40	$52,088.40	1,717
8/15/2017	Michael Patrick Miller	EVP	Sell	200	$144.38	$28,876.00	21,996
8/14/2017	Paul Treacy	SVP	Sell	1,304	$143.32	$186,889.28
8/11/2017	Paul L Berns	Director	Sell	662	$142.37	$94,248.94	6,599
7/20/2017	Suzanne Sawochka Hooper	EVP	Sell	4,580	$160.00	$732,800.00	32,322
7/17/2017	Michael Patrick Miller	EVP	Sell	200	$154.97	$30,994.00
6/23/2017	Suzanne Sawochka Hooper	EVP	Sell	420	$160.00	$67,200.00
6/15/2017	Michael Patrick Miller	EVP	Sell	200	$150.65	$30,130.00	22,223
6/1/2017	Rick E Winningham	Director	Sell	5,000	$150.00	$750,000.00	10,391
5/15/2017	Michael Patrick Miller	EVP	Sell	200	$152.98	$30,596.00	22,623
5/11/2017	Bruce C Cozadd	CEO	Sell	30,000	$153.47	$4,604,100.00	296,418
5/9/2017	Suzanne Sawochka Hooper	EVP	Sell	2,500	$160.00	$400,000.00	37,149
4/27/2017	Karen J Wilson	SVP	Sell	1,275	$160.00	$204,000.00	21,133
4/27/2017	Suzanne Sawochka Hooper	EVP	Sell	2,500	$160.00	$400,000.00	39,649
4/17/2017	Michael Patrick Miller	SVP	Sell	200	$152.56	$30,512.00	22,562
4/11/2017	Bruce C Cozadd	CEO	Sell	1,000	$152.12	$152,120.00	308,491
4/10/2017	Karen J Wilson	SVP	Sell	11,458	$152.24	$1,744,365.92	27,158
3/15/2017	Michael Patrick Miller	SVP	Sell	200	$137.89	$27,578.00	22,762
3/6/2017	Paul Treacy	SVP	Sell	884	$131.97	$116,661.48	18,108
2/15/2017	Michael Patrick Miller	SVP	Sell	200	$134.55	$26,910.00	16,486
1/18/2017	Russell J. Cox	COO	Sell	4,000	$128.75	$515,000.00
1/17/2017	Michael Patrick Miller	SVP	Sell	200	$115.93	$23,186.00	16,686
12/15/2016	Michael Patrick Miller	SVP	Sell	200	$103.09	$20,618.00
12/2/2016	Patrick G Enright	Director	Sell	677	$101.80	$68,918.60	1,365
11/15/2016	Michael Patrick Miller	SVP	Sell	200	$112.19	$22,438.00	16,925
11/14/2016	Kenneth W O'keefe	Director	Buy	2,000	$113.84	$227,680.00	12,107
10/17/2016	Michael Patrick Miller	SVP	Sell	200	$118.16	$23,632.00	17,125
9/19/2016	Michael Patrick Miller	SVP	Sell	200	$126.17	$25,234.00	17,325
8/25/2016	Seamus Mulligan	Director	Sell	27,968	$128.32	$3,588,853.76	1,072,411
8/16/2016	Paul Treacy	SVP	Sell	1,292	$137.47	$177,611.24
8/15/2016	Michael Patrick Miller	SVP	Sell	100	$136.45	$13,645.00	17,525
8/15/2016	Rick E Winningham	Director	Sell	633	$136.45	$86,372.85	15,391
8/12/2016	Karen L Smith	Insider	Buy	608	$137.10	$83,356.80	14,181
8/9/2016	Bruce C. Cozadd	CEO	Sell	1,000	$150.00	$150,000.00
8/9/2016	Russell J. Cox	COO	Sell	4,000	$148.66	$594,640.00
7/15/2016	Michael Patrick Miller	SVP	Sell	100	$142.43	$14,243.00	17,625
7/13/2016	Karen L Smith	CMO	Buy	580	$143.63	$83,305.40	13,574
6/15/2016	Michael Patrick Miller	SVP	Sell	100	$149.64	$14,964.00	17,725
6/13/2016	Karen L Smith	CMO	Buy	557	$149.61	$83,332.77	12,994
5/16/2016	Heather Ann Mcsharry	Director	Sell	697	$145.20	$101,204.40	5,396
5/16/2016	Michael Patrick Miller	SVP	Sell	100	$145.20	$14,520.00	17,753
4/25/2016	Karen J Wilson	SVP	Sell	604	$160.00	$96,640.00	18,059
4/15/2016	Michael Patrick Miller	SVP	Sell	100	$145.79	$14,579.00	18,792
4/13/2016	Karen J Wilson	SVP	Sell	5,007	$150.00	$751,050.00	18,663
4/12/2016	Russell J Cox	COO	Sell	4,000	$136.98	$547,920.00	60,470
4/7/2016	Karen J Wilson	SVP	Sell	2,161	$140.90	$304,484.90	23,670
3/15/2016	Michael Patrick Miller	SVP	Sell	100	$129.17	$12,917.00	18,892
3/8/2016	Bruce C Cozadd	CEO	Sell	2,500	$126.04	$315,100.00	302,566
2/29/2016	Paul Treacy	SVP	Sell	354	$123.48	$43,711.92	15,102
2/23/2016	Seamus Mulligan	Director	Sell	27,968	$122.71	$3,431,953.28	1,127,831
2/16/2016	Michael Patrick Miller	SVP	Sell	100	$115.63	$11,563.00	13,461
2/10/2016	Patrick G Enright	Director	Sell	10,000	$117.92	$1,179,200.00	1,310
2/9/2016	Bruce C Cozadd	CEO	Sell	2,500	$111.37	$278,425.00	281,896
1/15/2016	Michael Patrick Miller	SVP	Sell	100	$122.66	$12,266.00	13,561
1/12/2016	Bruce C Cozadd	CEO	Sell	2,500	$123.81	$309,525.00	284,396
1/5/2016	Patrick G Enright	Director	Sell	10,000	$138.09	$1,380,900.00	1,310
12/15/2015	Michael Patrick Miller	SVP	Sell	100	$136.99	$13,699.00	13,661
12/8/2015	Bruce C Cozadd	CEO	Sell	2,500	$139.72	$349,300.00	286,855
12/2/2015	Patrick G Enright	Director	Sell	10,424	$146.67	$1,528,888.08	1,310
11/23/2015	Seamus Mulligan	Director	Sell	27,968	$145.86	$4,079,412.48	1,130,547
11/10/2015	Bruce C Cozadd	CEO	Sell	2,500	$128.53	$321,325.00	289,355
11/10/2015	Patrick G Enright	Director	Sell	10,000	$135.29	$1,352,900.00	1,734
10/21/2015	Suzanne Sawochka Hooper	EVP	Sell	2,000	$125.00	$250,000.00	35,855
10/13/2015	Bruce C Cozadd	CEO	Sell	2,500	$131.50	$328,750.00	291,855
10/5/2015	Patrick G Enright	Director	Sell	10,000	$133.79	$1,337,900.00	1,734
9/25/2015	Michael Patrick Miller	SVP	Sell	100	$145.23	$14,523.00	13,890
9/8/2015	Bruce C. Cozadd	CEO	Sell	2,500	$163.07	$407,675.00	294,355
9/1/2015	Patrick G Enright	Director	Sell	10,000	$165.99	$1,659,900.00	1,734
7/14/2015	Bruce C Cozadd	CEO	Sell	5,000	$177.79	$888,950.00
7/14/2015	Suzanne Sawochka Hooper	EVP	Sell	4,000	$177.79	$711,160.00
7/6/2015	Patrick G Enright	Director	Sell	10,000	$177.11	$1,771,100.00
6/9/2015	Bruce C Cozadd	CEO	Sell	5,000	$173.16	$865,800.00
6/9/2015	Suzanne Sawochka Hooper	EVP	Sell	4,000	$173.16	$692,640.00
6/2/2015	Karen J Wilson	SVP	Sell	5,751	$179.59	$1,032,822.09
6/1/2015	Karen J Wilson	SVP	Sell	5,494	$179.57	$986,557.58
4/14/2015	Bruce C Cozadd	CEO	Sell	5,000	$181.45	$907,250.00
4/14/2015	Suzanne Sawochka Hooper	EVP	Sell	4,000	$181.45	$725,800.00
3/25/2015	Seamus Mulligan	Director	Sell	50,000	$174.59	$8,729,500.00
1/5/2015	Patrick G Enright	Director	Sell	10,000	$160.25	$1,602,500.00
12/26/2014	Seamus Mulligan	Director	Sell	50,000	$163.40	$8,170,000.00
12/12/2014	Patrick G Enright	Director	Sell	2,343	$170.98	$400,606.14
12/9/2014	Bruce C Cozadd	CEO	Sell	5,000	$178.79	$893,950.00
12/9/2014	Suzanne Sawochka Hooper	EVP	Sell	1,852	$178.79	$331,119.08
12/1/2014	Patrick G Enright	Director	Sell	10,000	$172.74	$1,727,400.00
11/24/2014	Jeffrey K Tobias	CMO	Sell	4,598	$170.12	$782,211.76
11/7/2014	Iain Mcgill	SVP	Sell	7,066	$172.03	$1,215,563.98
10/10/2014	Jeffrey K Tobias	CMO	Sell	1,000	$154.04	$154,040.00
10/6/2014	Patrick G Enright	Director	Sell	10,000	$160.56	$1,605,600.00
9/25/2014	Seamus Mulligan	Director	Sell	50,000	$163.16	$8,158,000.00
9/24/2014	Seamus Mulligan	Director	Sell	35,294	$163.70	$5,777,627.80
9/12/2014	Jeffrey K Tobias	CMO	Sell	1,000	$171.22	$171,220.00
9/11/2014	Karen J Wilson	SVP	Sell	3,000	$175.00	$525,000.00
9/11/2014	Seamus Mulligan	Director	Sell	50,000	$175.00	$8,750,000.00
9/9/2014	Bruce C Cozadd	CEO	Sell	5,000	$170.32	$851,600.00
9/8/2014	Karen J Wilson	SVP	Sell	2,500	$170.00	$425,000.00
9/8/2014	Suzanne Sawochka Hooper	EVP	Sell	1,852	$168.00	$311,136.00
8/12/2014	Bruce C Cozadd	CEO	Sell	5,000	$133.15	$665,750.00
8/12/2014	Suzanne Sawochka Hooper	EVP	Sell	1,185	$133.15	$157,782.75
8/11/2014	Jeffrey K Tobias	CMO	Sell	4,933	$135.42	$668,026.86
7/8/2014	Bruce C Cozadd	CEO	Sell	5,000	$155.00	$775,000.00
7/8/2014	Suzanne Sawochka Hooper	EVP	Sell	1,853	$155.00	$287,215.00
7/7/2014	Karen J Wilson	SVP	Sell	2,500	$165.00	$412,500.00
6/25/2014	Seamus Mulligan	Director	Sell	50,000	$149.69	$7,484,500.00
6/20/2014	Russell J Cox	COO	Sell	2,000	$155.00	$310,000.00
6/17/2014	Fintan Keegan	EVP	Sell	3,750	$150.00	$562,500.00
6/10/2014	Bruce C Cozadd	CEO	Sell	5,000	$142.34	$711,700.00
5/16/2014	Jeffrey Tobias	CMO	Sell	1,000	$128.01	$128,010.00	47,103
5/13/2014	Bruce Cozadd	CEO	Sell	5,000	$128.92	$644,600.00	606,810
4/17/2014	Rick Winningham	Director	Sell	27,500	$140.00	$3,850,000.00	13,587
4/14/2014	Jeffrey Tobias	CMO	Sell	3,000	$128.54	$385,620.00	48,103
4/8/2014	Bruce Cozadd	CEO	Sell	5,000	$123.18	$615,900.00	611,810
3/10/2014	Jeffrey Tobias	CMO	Sell	3,000	$152.99	$458,970.00	48,103
3/6/2014	Fintan Keegan	EVP	Sell	4,640	$159.90	$741,936.00	39,272
3/4/2014	Seamus Mulligan	Director	Sell	550,000	$156.25	$85,937,500.00	1,455,555
3/3/2014	Patrick Enright	Director	Sell	559,628	$152.39	$85,281,710.92

(Data available from 1/1/2013 forward)

Jazz Pharmaceuticals (NASDAQ JAZZ) News Headlines

Source:

Date	Headline
	Jazz Pharmaceuticals (JAZZ) Given a $210.00 Price Target by Royal Bank of Canada Analysts www.americanbankingnews.com - April 20 at 3:00 PM
	Jazz Pharmaceuticals (JAZZ) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 20 at 1:40 AM
	Jazz Pharmaceuticals (JAZZ) CFO Matthew P. Young Sells 700 Shares www.americanbankingnews.com - April 18 at 7:46 PM
	Jazz Pharmaceuticals (JAZZ) EVP Sells $31,498.00 in Stock www.americanbankingnews.com - April 13 at 7:27 PM
	BidaskClub Lowers Jazz Pharmaceuticals (JAZZ) to Sell www.americanbankingnews.com - April 13 at 4:23 PM
	Jazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to Hold www.americanbankingnews.com - April 13 at 10:02 AM
	Jazz Pharmaceuticals (JAZZ) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - April 12 at 7:25 PM
	Jazz Pharmaceuticals (JAZZ) SVP Karen J. Wilson Sells 3,899 Shares www.americanbankingnews.com - April 12 at 7:18 PM
	Jazz Pharmaceuticals (JAZZ) Receives Buy Rating from Janney Montgomery Scott www.americanbankingnews.com - April 12 at 2:19 PM
	Jazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by Royal Bank of Canada www.americanbankingnews.com - April 12 at 12:33 PM
	Jazz Pharmaceuticals' (JAZZ) "Outperform" Rating Reiterated at Cowen www.americanbankingnews.com - April 11 at 6:13 PM
	Jazz Pharmaceuticals (JAZZ) Receives "Outperform" Rating from Wells Fargo www.americanbankingnews.com - April 11 at 4:31 PM
	Jazz Pharmaceuticals' (JAZZ) Buy Rating Reiterated at Piper Jaffray www.americanbankingnews.com - April 10 at 10:31 PM
	$434.02 Million in Sales Expected for Jazz Pharmaceuticals (JAZZ) This Quarter www.americanbankingnews.com - April 10 at 2:38 AM
	Analysts Expect Jazz Pharmaceuticals (JAZZ) to Post $2.73 EPS www.americanbankingnews.com - April 8 at 5:20 PM
	Jazz Pharmaceuticals (JAZZ) Given a $175.00 Price Target by Seaport Global Securities Analysts www.americanbankingnews.com - April 6 at 2:28 PM
	Insider Selling: Jazz Pharmaceuticals plc - (JAZZ) CEO Sells 1,000 Shares of Stock www.americanbankingnews.com - April 4 at 11:17 PM
	Jazz Pharmaceuticals (JAZZ) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 2 at 7:30 PM
	Royal Bank of Canada Lowers Jazz Pharmaceuticals (JAZZ) Price Target to $195.00 www.americanbankingnews.com - April 1 at 11:24 AM
	Royal Bank of Canada Reaffirms "Outperform" Rating for Jazz Pharmaceuticals (JAZZ) www.americanbankingnews.com - April 1 at 11:24 AM
	Jazz Pharmaceuticals (JAZZ) Given a $170.00 Price Target by Deutsche Bank Analysts www.americanbankingnews.com - March 28 at 2:07 PM
	Jazz Pharmaceuticals (JAZZ) Earns "Buy" Rating from B. Riley www.americanbankingnews.com - March 28 at 12:58 PM
	Jazz Pharmaceuticals plc - (JAZZ) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 26 at 1:50 AM
	Jazz Pharmaceuticals plc - (JAZZ) Expected to Post Quarterly Sales of $432.77 Million www.americanbankingnews.com - March 24 at 4:14 AM
	HC Wainwright Reiterates Hold Rating for Jazz Pharmaceuticals (JAZZ) www.americanbankingnews.com - March 23 at 2:57 PM
	$2.73 Earnings Per Share Expected for Jazz Pharmaceuticals plc - (JAZZ) This Quarter www.americanbankingnews.com - March 22 at 5:20 PM
	Jazz Pharmaceuticals plc - (JAZZ) CFO Sells $105,854.00 in Stock www.americanbankingnews.com - March 19 at 8:14 PM
	Jazz Pharmaceuticals (JAZZ) Stock Rating Upgraded by Morgan Stanley www.americanbankingnews.com - March 19 at 6:12 PM
	Jazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to "Sell" www.americanbankingnews.com - March 18 at 6:06 PM
	Jazz Pharmaceuticals plc - (JAZZ) EVP Michael Patrick Miller Sells 200 Shares www.americanbankingnews.com - March 16 at 8:52 PM
	Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock? finance.yahoo.com - March 16 at 6:30 PM
	Jazz Pharmaceuticals plc - (JAZZ) CEO Bruce C. Cozadd Sells 1,000 Shares www.americanbankingnews.com - March 13 at 8:17 PM
	Jazz Pharmaceuticals (JAZZ) Shares Cross Above 200 DMA - Nasdaq - Nasdaq www.nasdaq.com - March 9 at 8:19 AM
	Jazz Pharmaceuticals plc - (JAZZ) SVP Sells $84,033.18 in Stock www.americanbankingnews.com - March 7 at 7:30 PM
	Jazz Pharmaceuticals plc - (JAZZ) CFO Matthew P. Young Sells 1,152 Shares www.americanbankingnews.com - March 7 at 7:12 PM
	Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March finance.yahoo.com - March 6 at 5:41 PM
	BlackRock Inc. Has $378.66 Million Stake in Jazz Pharmaceuticals plc - (JAZZ) www.americanbankingnews.com - March 6 at 5:02 AM
	Jazz Pharmaceuticals plc - (JAZZ) SVP Sells $122,446.74 in Stock www.americanbankingnews.com - March 5 at 7:18 PM
	Jazz Pharmaceuticals plc - (JAZZ) Expected to Announce Earnings of $2.73 Per Share www.americanbankingnews.com - March 5 at 1:18 PM
	OppenheimerFunds Inc. Reduces Position in Jazz Pharmaceuticals plc - (JAZZ) www.americanbankingnews.com - March 5 at 10:07 AM
	Aviance Capital Partners LLC Has $2.17 Million Holdings in Jazz Pharmaceuticals plc - (JAZZ) www.americanbankingnews.com - March 5 at 4:45 AM
	Suntrust Banks Inc. Reduces Position in Jazz Pharmaceuticals plc - (JAZZ) www.americanbankingnews.com - March 4 at 11:04 AM
	Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA ... - StreetInsider.com www.streetinsider.com - March 4 at 8:15 AM
	Jazz Pharmaceuticals plc - (JAZZ) Shares Bought by Maverick Capital Ltd. www.americanbankingnews.com - March 4 at 8:02 AM
	Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA for Solriamfetol www.streetinsider.com - March 3 at 6:27 PM
	Jazz Pharmaceuticals plc - (JAZZ) Shares Bought by UBS Asset Management Americas Inc. www.americanbankingnews.com - March 3 at 9:08 AM
	Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness ... - PR Newswire (press release) www.prnewswire.com - March 3 at 8:15 AM
	State of Wisconsin Investment Board Sells 844 Shares of Jazz Pharmaceuticals plc - (JAZZ) www.americanbankingnews.com - March 2 at 7:50 PM
	BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea www.reuters.com - March 2 at 6:12 PM
	Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea finance.yahoo.com - March 2 at 6:12 PM

Jazz Pharmaceuticals (NASDAQ:JAZZ) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Income Statement, Balance Sheet and Cash Flow Statement

Jazz Pharmaceuticals (NASDAQ JAZZ) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff